Early phase 2 studies (NCT02443116) of aldafermin (NGM282, a nontumorigenic FGF19 variant) showed efficacy in reducing hepatic steatosis and hepatic inflammation/fibrosis in patients with NASH [77]. This evidence concerns the gene FGF19 and metabolic dysfunction-associated steatohepatitis.